Activating RAS Mutation clinical trials at UCSF
1 research study open to new patients
open to eligible people ages 2-21
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
San Francisco, California and other locations